ATM participates in the regulation of viability and cell cycle via ellipticine in bladder cancer

Tao,Shuixiang; Meng,Shuai; Zheng,Xiangyi; Xie,Liping

doi:10.3892/mmr.2017.6141

ATM participates in the regulation of viability and cell cycle via ellipticine in bladder cancer

Authors:
- Shuixiang Tao
- Shuai Meng
- Xiangyi Zheng
- Liping Xie
View Affiliations

Affiliations: Department of Urology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310003, P.R. China
Published online on: January 24, 2017 https://doi.org/10.3892/mmr.2017.6141
Pages: 1143-1148
Copyright: © Tao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Ellipticine, an alkaloid isolated from Apocyanaceae plants, has been demonstrated to exhibit antitumor activity in several cancers. However, the effect and the mechanisms underlying its action have not been investigated in human bladder cancer cells. The aim of the present study was to investigate the effect and mechanism of ellipticine on the behavior of T‑24 bladder cancer cells. T‑24 cells were treated with varying concentrations and durations of ellipticine. Cell viability was evaluated by Cell Counting Kit‑8 assay. Cell motility was analyzed by Transwell migration assay. Flow cytometry, reverse transcription‑quantitative polymerase chain reaction and western blot analyses were performed to detect the cell cycle and signaling pathways involved. The results demonstrated that ellipticine suppressed proliferation and inhibited the migration ability of T‑24 bladder cancer cells in a dose‑ and time‑dependent manner, and resulted in G2/M cell cycle arrest. The mechanism of this action was demonstrated to be due to ellipticine‑triggered activation of the ATM serine/threonine kinase pathway. These data therefore suggest that ellipticine may be effective towards treating human bladder cancer.

View Figures

View References

1	Goodwin S, Smith AF and Horning EC: Alkaloids of ochrosia elliptica labill. J Am Chem Soc. 81:1903–1908. 1959. View Article : Google Scholar
2	Rouësse JG, Le Chevalier T, Caille P, Mondesir JM, Sancho-Garnier H, May-Levin F, Spielmann M, De Jager R and Amiel JL: Phase II study of elliptinium in advanced breast cancer. Cancer Treat Rep. 69:707–708. 1985.PubMed/NCBI
3	Stiborová M, Bieler CA, Wiessler M and Frei E: The anticancer agent ellipticine on activation by cytochrome P450 forms covalent DNA adducts. Biochem Pharmacol. 62:1675–1684. 2001. View Article : Google Scholar : PubMed/NCBI
4	Auclair C: Multimodal action of antitumor agents on DNA: The ellipticine series. Arch Biochem Biophys. 259:1–14. 1987. View Article : Google Scholar : PubMed/NCBI
5	Martinkova E, Maglott A, Leger DY, Bonnet D, Stiborova M, Takeda K, Martin S and Dontenwill M: alpha5beta1 integrin antagonists reduce chemotherapy-induced premature senescence and facilitate apoptosis in human glioblastoma cells. Int J Cancer. 127:1240–1248. 2010. View Article : Google Scholar : PubMed/NCBI
6	Kuo PL, Hsu YL, Kuo YC, Chang CH and Lin CC: The anti-proliferative inhibition of ellipticine in human breast mda-mb-231 cancer cells is through cell cycle arrest and apoptosis induction. Anticancer Drugs. 16:789–795. 2005. View Article : Google Scholar : PubMed/NCBI
7	Kuo YC, Kuo PL, Hsu YL, Cho CY and Lin CC: Ellipticine induces apoptosis through p53-dependent pathway in human hepatocellular carcinoma HepG2 cells. Life Sci. 78:2550–2557. 2006. View Article : Google Scholar : PubMed/NCBI
8	Fang K, Chen SP, Lin CW, Cheng WC and Huang HT: Ellipticine-induced apoptosis depends on Akt translocation and signaling in lung epithelial cancer cells. Lung Cancer. 63:227–234. 2009. View Article : Google Scholar : PubMed/NCBI
9	Chavan S, Bray F, Lortet-Tieulent J, Goodman M and Jemal A: International variations in bladder cancer incidence and mortality. Eur Urol. 66:59–73. 2014. View Article : Google Scholar : PubMed/NCBI
10	Amsellem-Ouazana D, Bièche I, Tozlu S, Botto H, Debre B and Lidereau R: Gene expression profiling of ERBB receptors and ligands in human transitional cell carcinoma of the bladder. J Urol. 175:1127–1132. 2006. View Article : Google Scholar : PubMed/NCBI
11	Pliarchopoulou K, Laschos K and Pectasides D: Current chemotherapeutic options for the treatment of advanced bladder cancer: A review. Urol Oncol. 31:294–302. 2013. View Article : Google Scholar : PubMed/NCBI
12	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
13	Peng CY, Graves PR, Thoma RS, Wu Z, Shaw AS and Piwnica-Worms H: Mitotic and G2 checkpoint control: Regulation of 14–3-3 protein binding by phosphorylation of Cdc25C on serine-216. Science. 277:1501–1505. 1997. View Article : Google Scholar : PubMed/NCBI
14	Stiborova M, Poljakova J, Eckschlager T, Kizek R and Frei E: Analysis of covalent ellipticine- and doxorubicin-derived adducts in DNA of neuroblastoma cells by the ³²P-postlabeling technique. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 156:115–121. 2012. View Article : Google Scholar : PubMed/NCBI
15	Ghosh S, Kar A, Chowdhury S and Dasgupta D: Ellipticine binds to a human telomere sequence: An additional mode of action as a putative anticancer agent? Biochemistry. 52:4127–4137. 2013. View Article : Google Scholar : PubMed/NCBI
16	Zhou BB and Elledge SJ: The DNA damage response: Putting checkpoints in perspective. Nature. 408:433–439. 2000. View Article : Google Scholar : PubMed/NCBI
17	Helt CE, Cliby WA, Keng PC, Bambara RA and O'Reilly MA: Ataxia telangiectasia mutated (ATM) and ATM and Rad3-related protein exhibit selective target specificities in response to different forms of DNA damage. J Biol Chem. 280:1186–1192. 2005. View Article : Google Scholar : PubMed/NCBI
18	Thanasoula M, Escandell JM, Suwaki N and Tarsounas M: ATM/ATR checkpoint activation downregulates CDC25C to prevent mitotic entry with uncapped telomeres. EMBO J. 31:3398–3410. 2012. View Article : Google Scholar : PubMed/NCBI
19	Graves PR, Lovly CM, Uy GL and Piwnica-Worms H: Localization of human Cdc25C is regulated both by nuclear export and 14-3-3 protein binding. Oncogene. 20:1839–1851. 2001. View Article : Google Scholar : PubMed/NCBI
20	Taylor WR and Stark GR: Regulation of the G2/M transition by p53. Oncogene. 20:1803–1815. 2001. View Article : Google Scholar : PubMed/NCBI
21	Kim JY, Lee SG, Chung JY, Kim YJ, Park JE, Koh H, Han MS, Park YC, Yoo YH and Kim JM: Ellipticine induces apoptosis in human endometrial cancer cells: The potential involvement of reactive oxygen species and mitogen-activated protein kinases. Toxicology. 289:91–102. 2011. View Article : Google Scholar : PubMed/NCBI
22	Kuo PL, Hsu YL, Chang CH and Lin CC: The mechanism of ellipticine-induced apoptosis and cell cycle arrest in human breast MCF-7 cancer cells. Cancer Lett. 223:293–301. 2005. View Article : Google Scholar : PubMed/NCBI